

# CNS Infection II

## Fungal and Parasitic Infection of CNS

Sirigunya Roongruang, M.D.

Adviser : Abhinbhen Saraya Wasontiwong, MD. MSc

# Main Pathogens that cause fungal infection of CNS


- Cryptococcus species
- Aspergillus species
- Candida species
- Mucormycosis



# Fungal infection of CNS : Morphological Classifications


## MOLDS

**Septate hyphae**  
: *Aspergillus spp.*



Weisenberg E. Aspergillus. PathologyOutlines.com


**Aseptate hyphae**  
: *Mucor spp.*



A.J. Layon et al. (eds.), Central Nervous System Infection Textbook of Neurointensive Care, DOI 10.1007/978-1-4471-5226-2\_22,


## YEAST

**Candida**  
: *C.albicans*



Funk, Irina & Sieber, Volker & Schmid, Jochen. (2017). Effects of glucose concentration on 1,18-cis-octadec-9-enedioic acid biotransformation efficiency and lipid body formation in Candida tropicalis. Scientific Reports.

**Cryptococcus**  
: *C.neoforman*  
*C.gattii*




Schein JE, Tangen KL, Chiu R, Shin H, Lengeler KB, MacDonald WK, Bosdet I, Heitman J, Jones SJ, Marra MA, Kronstad JW. Physical maps for genome analysis of serotype A and D strains of the fungal pathogen *Cryptococcus neoformans*. Genome Res. 2002;12: 1445-53.

# Cryptococcal Meningitis

# Cryptococcal Meningitis

## Pathogenesis



# Pathogenic cryptococci

- ***Cryptococcus neoformans***

- Reservoir - Bird excreta

- Infected mainly in Immunocompromised host

CNS > LUNGS

More susceptible to fluconazole

- ***Cryptococcus gattii***

- Reservoir - Eucalyptus tree

- Infected mainly in immunocompetent host

LUNGS > CNS

Less susceptible to fluconazole



# Cryptococcal Meningitis

## Epidemiology

- **HIV associated cryptococcal infection**
  - Patients at risk : CD4+ T cell counts  $<100$  cells/ $\mu$ l and not on effective antiretroviral therapy (ART)
- Infection in **HIV-negative** individuals : transplant recipients and other patients with defects in cell-mediated immunity

# Cryptococcal Meningitis

## Box 2 | Predisposing genetic and other conditions in non-HIV CM

### Syndromes and autoantibodies

- Idiopathic CD4<sup>+</sup> lymphopenia<sup>22,23</sup>
- Pulmonary alveolar proteinosis with autoantibodies to GM-CSF<sup>24–26</sup>
- Autoantibodies to IFN- $\gamma$ <sup>27</sup>

### Monogenic disorders

- Primary immunodeficiency owing to *GATA2* mutations<sup>28–30</sup>
- Chronic granulomatous disease
- Hyperimmunoglobulin E recurrent infection syndrome (also known as Job syndrome)<sup>31,32</sup>
- X-Linked CD40L deficiency (also known as hyper-IgM syndrome)<sup>33,34</sup>

### Polygenetic modifiers

- FC $\gamma$  receptor II polymorphism<sup>35</sup>

### Comorbidities<sup>18,19</sup>

- Sarcoidosis, autoimmune disease, steroid treatment
- Hepatic disease
- Solid organ transplant conditioning

CM, cryptococcal meningitis; GM-CSF, granulocyte-macrophage colony stimulating factor.

# Cryptococcal Meningitis

## Clinical Features

- **Subacute meningoencephalitis**
  - : most typically headache and altered mental status, fever, nausea and vomiting
- The median duration from symptom onset to presentation
  - 2 weeks in patients with HIV infection
  - 6–12 weeks in non-HIV CM cases

Many patients develop visual symptoms, such as diplopia and, later in the disease, reduced acuity secondary to high CSF pressure and/or involvement of the optic nerve and tracts

# Cryptococcus Meningitis

## Diagnosis and Investigation

- Characteristic CSF :
  - Elevated white cell count
  - Lymphocyte predominance
  - Elevated CSF protein
  - Low CSF glucose

1/2 of HIV-infected patients with CM have a CSF opening pressure of >25 cmH<sub>2</sub>O, High pressure is associated with worse symptoms, including headache, nausea, diplopia secondary to 6th nerve palsies, and altered mental status

In HIV- associated cryptococcal meningitis

CSF white cell count is lower (median  $15 \times 10^6$  cells/l) and can often be normal



# Cryptococcus Meningitis

## Diagnosis and Investigation : Cryptococcus capsular polysaccharide antigen

- Cryptococcus capsular polysaccharide antigen (CrAg) in CSF, serum, plasma or whole blood is key to rapid diagnosis of cryptococcal meningitis
- CrAg lateral flow assay (LFA) **Sensitivity and Specificity 99%** with whole blood, serum and plasma, being nearly as accurate for diagnosis of meningitis

# Cryptococcus Meningitis

## Cryptococcus capsular polysaccharide antigen titer

Both latex agglutination and CrAg LFA can be semiquantified using titers

Titer between the Immy latex agglutination test and Immy LFA are **not** comparable

CrAg titer is predictive of meningitis and death



Plasma CrAg titers of 1:80 by Immy CrAg have an exceedingly low probability of meningitis

CrAg titers of 1:1,280 have near-universal CNS involvement

# Cryptococcus Meningitis

## Diagnosis and Investigation : Cryptococcus capsular polysaccharide antigen

- **Lower sensitivity (91%)** has been noted with **high fungal burdens** due to the **pro-zone or hook effect** : High cryptococcal load interfering with antigen–antibody complex of the assay resulting in a false negative) >>>> this issue resolves **with dilution (sensitivity 100%)**



A dose response assay illustrating the hook effect. At high concentrations of analyte, a lower signal is observed. This shows that using this assay to determine the concentration of analyte in a sample containing very high levels would produce a lower signal. Since this signal normally correlates to a lower concentration, an inaccurately low result is recorded.

# Cryptococcus Meningitis

## Diagnosis and Investigation

- India Ink , sensitivity is as low as 42% when fungal burden is <1000 CFU/ml, and the best case is 85% sensitivity
- Fungal culture, growth can take up to 10 days and false- negative results can occur with a low fungal burden

# Cryptococcus Meningitis

## Diagnosis and Investigation

- Quantitative culture, useful for
  - Monitoring response to treatment
  - **Differentiating relapse** of cryptococcal meningitis from **IRIS**

A paired comparison : Quantitative CSF culture and CSF Cr Ag

no significant difference between their results of the two assays ( $P = .09$  by paired t-test)


Reproducibility of CSF quantitative culture methods for *Cryptococcus neoformans* April 2014, International Journal of Infectious Diseases 21(S1):286

Poplin, V., Boulware, D. R., & Bahr, N. C. (2020). Methods for rapid diagnosis of meningitis etiology in adults. *Biomarkers in medicine*, 14(6), 459–479.





# Cryptococcus Meningitis

## Features on Neuroimaging



(Left) Coronal graphic shows multiple dilated perivascular (Virchow-Robin) spaces, filled with fungi and mucoid material, resulting in **gelatinous pseudocysts** which are characteristic of cryptococcal infection in AIDS

(Right) Axial T2WI MR shows multiple **dilated perivascular spaces** in this immunocompromised patient with cryptococcal meningitis. **Gelatinous pseudocysts are most commonly located in the basal ganglia and thalami** but may be seen in the brainstem, cerebellum, and cerebral hemispheres.



(Left) Axial FLAIR MR shows bilateral dilated perivascular spaces with hyperintense rims in this AIDS patient with Cryptococcus meningitis. **Hydrocephalus** is a common complication of this infection

(Right) Axial T1WI C+ MR in the same patient shows subependymal enhancement **along the frontal horns of the lateral ventricles as well as nodular leptomeningeal enhancement**. Enhancement in Cryptococcus infection is dependent on the cell-mediated immunity of the host.



Stage	Pharmacological treatment regimen	Duration
Induction	L-AmB 3–6 mg/kg daily or D-AmB 0.7–1.0 mg/kg daily (L-AmB preferred in organ transplant patients and when >2-week induction is needed) in combination with flucytosine 100 mg/kg daily (75 mg/kg daily if intravenous formulation is used)	<ul style="list-style-type: none"> <li>• HIV+ patients: 2 weeks</li> <li>• Transplant recipients:* ≥2 weeks</li> <li>• For all other patients, including patients with <i>Cryptococcus gatti</i> infection:* 4–6 weeks</li> </ul>
Consolidation	<ul style="list-style-type: none"> <li>• Fluconazole 400–800 mg daily‡</li> <li>• In HIV+ patients, start ART at 4 weeks</li> </ul>	8 weeks
Maintenance therapy	<ul style="list-style-type: none"> <li>• Fluconazole 200 mg daily</li> <li>• In HIV+ patients, consider discontinuing maintenance after a minimum of 1 year if CD4+ cell count is &gt;100 cells/μL and HIV viral load is suppressed</li> </ul>	≥1 year
Induction therapy in resource-limited settings	<ul style="list-style-type: none"> <li>• If flucytosine is not available:</li> <li>• D-AmB 0.7–1 mg/kg daily intravenously in combination with fluconazole 800–1200 mg daily</li> </ul>	2 weeks (1 week is better than no D-AmB)
	<ul style="list-style-type: none"> <li>• If D-AmB is not available:</li> <li>• Fluconazole 1,200 mg daily§ in combination with flucytosine 100 mg/kg daily orally (if available)</li> </ul>	2 weeks

ART, antiretroviral therapy; D-AmB, amphotericin B deoxycholate; L-AmB, liposomal amphotericin B. \*see IDSA guidelines<sup>78</sup>. ‡800 mg daily preferred if second line induction regimens used. §Fluconazole increases nevirapine levels, and safety of high-dose fluconazole with nevirapine is unknown. Alternative antiretrovirals are preferred.



# Amphotericin B deoxycholate (D-AmB)

Amphotericin B deoxycholate (D-AmB) associated with

- Renal impairment
- Hypokalaemia
- Hypomagnesaemia
- Anaemia

- Saline and fluid loading equivalent to giving 1 l of regular saline per day in addition to usual fluid requirements, has been shown to reduce renal impairment

- Liposomal amphotericin B (L-AmB) is equally as effective as D-AmB, and is better tolerated

The rate of clearance of infection derived from quantitative cultures of CSF from **serial lumbar punctures** over the **first 2 weeks of treatment** provides a statistically powerful and clinically relevant endpoint



# Cryptococcal Meningitis

## Treatment

Therapeutic LP are recommended to control high CSF pressure

The safe maximum volume of CSF that can be drained at one lumbar puncture is unclear, but up to 30 ml are frequently removed in patients with high pressure, with checking of pressure after each 10 ml removed

# Cryptococcal Meningitis

## Treatment

### **CSF opening pressure of >25 cmH2O**

: LP to reduce OP 50% or to normal [20 cmH2O]

### **Persistent pressure >25 cmH2O with symptoms**

: Repete LP daily until stabilized for > 2 days

Consider temporary percutaneous lumbar drains or ventriculostomy

Permanent VP shunts when Fail conservative measures

# Cryptococcal Meningitis

## Treatment

- In patients **without HIV**, the clinical response depends on **control** of aberrant **immune responses** as much as it depends on control of the initial infection
- Initial therapy with amphotericin B and flucytosine is similar to that for HIV-related disease, but the **induction phase is longer** (4–6 weeks)

Lipid formulations have been favoured over the deoxycholate preparation because of reduced renal toxicity

Post-transplant cryptococcosis : **Discontinuation of calcineurin agents** (Tacrolimus, reducing IL-2 production and receptor expression, leading to reduction in T-cell activation) has been associated with clinical **deterioration and IRIS**

# Cryptococcal IRIS

# Paradoxical IRIS

: 1–2 months after ART initiation

## Risk factors for CM-IRIS

Low pre-ART CD4+ cell count that rises rapidly after ART initiation

A low initial CSF white cell count

Low markers of inflammation and IFN- $\gamma$  responses on initial presentation

High fungal burden at baseline and day 14

# Unmasking IRIS

Lower fungal burden compared with ART-naive cases

Unmasking CM-IRIS are treated with the **same antifungal regimens** used for those who are ART-naive

# Paradoxical IRIS

: 1–2 months after ART initiation

## Risk factors for CM-IRIS

Low pre-ART CD4+ cell count that rises rapidly after ART initiation

A low initial CSF white cell count

Low markers of inflammation and IFN- $\gamma$  responses on initial presentation

High fungal burden at baseline and day 14

Cryptococcal Optimal ART Timing (COAT) study

Patients given early ART (median initiation at 8 days)

Higher CSF WBC and CSF markers of macrophage and/or microglial activation than patients not yet started on ART

suggesting the excess deaths in the early ART arm may have been immune mediated

**Current guidelines suggest that ART is initiated at 4–6 weeks**

Boulware, D. R. et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. *N. Engl. J. Med.* 370, 2487–2498 (2014).



# Paradoxical IRIS

: 1–2 months after ART initiation

## Risk factors for CM-IRIS

Low pre-ART CD4+ cell count that rises rapidly after ART initiation

A low initial CSF white cell count

Low markers of inflammation and IFN- $\gamma$  responses on initial presentation

High fungal burden at baseline and day 14

Patients who re-present (worsening ) after the start of ART should

- LP to screening for ongoing infection + C/S
- Re-induction anti fungal therapy  
L-AmB 3-6 mg/kg/day or D-AmB 0.7-1 mg/kg/day
- **Short course corticosteroid**

Boulware, D. R. et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. *N. Engl. J. Med.* 370, 2487–2498 (2014).

## Paradoxical IRIS

: 1–2 months after ART initiation

### Risk factors for CM-IRIS

Low pre-ART CD4+ cell count that rises rapidly after ART initiation

A low initial CSF white cell count

Low markers of inflammation and IFN- $\gamma$  responses on initial presentation

High fungal burden at baseline and day 14

## Unmasking IRIS


Lower fungal burden compared with ART-naive cases

Unmasking CM-IRIS are treated with the **same antifungal regimens** used for those who are ART-naive




# Host damage from infection-related inflammatory syndromes in HIV-positive and in HIV-negative cryptococcal meningitis

## CM-IRIS



## PIIRS : Post-infectious inflammatory response syndromes





**Corticosteroid treatment can reduce brain oedema in patients with HIV-negative cryptococcal meningitis**

MRI scans demonstrate reduced brain oedema (arrows) after treatment with corticosteroids in an HIV-negative patient with CM and PIIRS

T1 and FLAIR weighted MRI scans of a patient with *Cryptococcus gattii* infection and autoantibody against granulocyte-macrophage colony stimulating factor treated with amphotericin B. Corticosteroid therapy was stopped on day 24, but then reinstated at day 34–66 after clinical deterioration.



# Screening and Prevention

- Antigen was detectable in the blood at a median of 22 days before development of CNS symptoms
- Retrospective cohort study of over 700 prospectively monitored patients in Cape Town, South Africa, blood samples were taken before initiation of ART
- None of the 661 patients who were cryptococcal antigen negative (93%) went on to develop CM in the first year of ART
- By contrast, at least 7 of 25 patients (28%) who were antigen- positive with no prior history of CM developed CM during this time

French, N. et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. *AIDS* 16, 1031–1038 (2002).

Jarvis, J. N. et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. *Clin. Infect. Dis.* 48, 856–862 (2009).

# Screening and Prevention

## Pre-emptive therapy strategy

**Patients at risk (with CD4+ T cell counts <100 cells/ $\mu$ l) are tested for antigen and those who tested positive are given pre-emptive therapy with the widely available and safe oral fluconazole**

- None of the 661 patients who were cryptococcal antigen negative (93%) went on to develop CM in the first year of ART
- By contrast, at least 7 of 25 patients (28%) who were antigen- positive with no prior history of CM developed CM during this time


French, N. et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. *AIDS* 16, 1031–1038 (2002).

Jarvis, J. N. et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. *Clin. Infect. Dis.* 48, 856–862 (2009).

# CNS Aspergillosis


# Invasive Aspergillosis

## Pathogenesis



# Invasive Aspergillosis


## Pathogenesis





# Invasive Aspergillosis

## Pathogenesis





# Invasive Aspergillosis

- 70% of invasive mold infection
- Commonly caused by *Aspergillus fumigatus*
- Risk Factors
  - Neutropenia
  - Chemotherapy
  - Corticosteroid use
  - Transplants ( Stem cell or solid organ)

# Aspergillus species

Immunosuppressive gliotoxin and enzymes (proteases, elastases and phospholipases) which hinder the host immune response and facilitate tissue penetration

## Clinical Symptoms


- Aspergillosis is **angioinvasive**, and neurologic manifestations most frequently involve a **CNS vasculitis** of small and medium-sized arteries
- Meningeal involvement is a less common complication and, when present, is typically associated with vasculitis and brain abscesses
- Invasive CNS aspergillosis involving the meninges may also result from **direct invasion** from **adjacent sinonasal structures**, although this occurs much more rarely than hematogenous spread




# Diagnosis of Invasive Aspergillosis

## Definite case

Histopathology : Septate hyphae with acute angle branching



PAS stains Contributed by Dr. Claudia Mendez, Bogota, Columbia.



Autopsy specimen shows aspergillosis invading the paranasal sinuses and skull base. One internal carotid artery is encased by fungus while the other has been occluded .  
(Courtesy R. Hewlett, MD.)



# Diagnosis of Invasive Aspergillosis

**CSF fungal culture** is only 31% sensitive among all hosts, and 18% in immunocompromised hosts

**Galactomannan antigen** is a cell wall polysaccharide released by *Aspergillus* that can be detected in body fluids including CSF,

**CSF galactomannan sensitivity is 70–90% and specificity 70–100%**

CSF *Aspergillus* PCR was 75% sensitive


although larger studies are needed to establish the utility of CSF PCR for diagnosis of CNS aspergillosis

**Aspergillus antibody** detection in CSF is possible but performance is unreliable




# CNS Aspergillosis

## Features on Neuroimaging





Axial CECT in an immunosuppressed patient shows a large, low-density mass in the right frontal lobe and deep basal ganglia with irregular rim enhancement and surrounding edema fit with local mass effect. Aspergilloma abscess was found at surgery.



Axial NECT in an immunosuppressed patient shows multifocal parenchymal hemorrhages at the gray- white matter interface. Hemorrhagic mycetomas from angioinvasive aspergillosis were documented at surgery.



# CNS Aspergillosis



(Left) Axial SWI image in the same patient shows areas of hemorrhage in the regions of diffusion abnormality. (Right) Axial T1+C MR in the same patient does not demonstrate any abnormal enhancement in the frontal lobes or left thalamus. Biopsy of the right frontal lobe lesion revealed invasive aspergillosis. Aspergillus infections leads to an infectious vasculopathy resulting in acute infarction, hemorrhage, and cerebritis/abscess.



# 2016 IDSA Guidelines for Management of Invasive Aspergillosis

## Primary Treatment

**Voriconazole** for CNS aspergillosis (strong recommendation)

Duration : at least 6-12 weeks

## Alternative Treatment


Lipid formulations of AmB are reserved for those intolerant or refractory to voriconazole (strong recommendation; moderate-quality evidence)

Candida species



# Invasive Candidiasis


## Pathogenesis



Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015 Oct 8;373(15):1445-56. doi: 10.1056/NEJMra1315399. PMID: 26444731.



# Pathogenesis



# Invasive Candidiasis

is most often caused by *C. albicans*

## Risk Factors

Long-term Use of Broad-Spectrum Antibiotics


Breach of GI and Cutaneous barriers : Inflammation/Perforation

Central Vascular Catheters : TPN, HD

Immunosuppression : Chemotherapy-induced neutropenia, Steroid therapy

Hematologic malignancy disease

Solid-organ tumors




Effector mechanisms of myeloid phagocytes for control of invading *Candida* spp. in infected tissue.



# Invasive Candidiasis

is most often caused by *C. albicans*




Effector mechanisms of myeloid phagocytes for control of invading *Candida* spp. in infected tissue.

Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015 Oct 8;373(15):1445-56. doi: 10.1056/NEJMra1315399. PMID: 26444731.



# Invasive Candidiasis

is most often caused by *C. albicans*




Effector mechanisms of myeloid phagocytes for control of invading *Candida* spp. in infected tissue.

Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015 Oct 8;373(15):1445-56. doi: 10.1056/NEJMra1315399. PMID: 26444731.




# Recognition of *Candida* spp. by pattern recognition receptors of myeloid phagocytes.



From Review literature , AR CARD9 deficiency, invasive candidiasis typically affects CNS, from case report CARD9 deficiency identified 60 patients with 24 mutations





# Recognition of *Candida* spp. by pattern recognition receptors of myeloid phagocytes.



From Review literature , AR CARD9 deficiency, invasive candidiasis typically affects CNS, from case report CARD9 deficiency identified 60 patients with 24 mutations



# Species Distribution of Candida in Asia





# Candida cerebral abscesses

## Main Clinico-pathological disease groups

1. Cerebral microabscesses
2. Meningitis
3. Cerebral macroabscesses
4. Vascular complications

Hematogenous spread is likely a frequent source for the development of Candida cerebral abscess, but blood cultures revealed candidemia in only 55%

Lumbar puncture, Candida growth in only 23% of cases

# Diagnostic Tests for Invasive Candidiasis

**Table 2. Performance of Blood Cultures in Autopsy Studies of Invasive Candidiasis**

Reference	Year	No. of Patients	Underlying Disease	Sensitivity
Louria (from [13])	1962	19	Hematologic malignancies, solid tumors, medical and surgical conditions	42%
Bodey (from [13])	1966	61	Acute leukemia	25%
Taschdjian (from [13])	1969	17	Malignancies and other medical conditions	47%
Hart (from [13])	1969	16	Hematologic malignancies, solid tumors, transplant, medical and surgical conditions	44%
Bernhardt (from [13])	1972	14	Transplant and surgical conditions	36%
Gaines (from [13])	1973	26	Hematologic malignancies, solid tumors, medical and surgical conditions	54%
Myerowitz (from [13])	1977	39	Hematologic malignancies, solid tumors, medical and surgical conditions	44%
Ness [9]	1989	7	Hematologic malignancies and bone marrow transplant recipients	71%
Singer [37]	1977	16	Hematologic malignancies	31%
Berenguer [13]	1993	37	Mostly hematologic malignancies and solid tumors	43%
Van Burik [38]	1998	62	Bone marrow transplant recipients	52%
Kami [39]	2002	91	Hematologic malignancies	21%
Thorn [40]	2010	10	Hematologic malignancies, gastrointestinal disease, transplant, prematurity	50%



Diagnostic test	Specimen(s)	Advantages	Disadvantages
Fungal culture	Blood	<ul style="list-style-type: none"> <li>• Enables species identification and subsequent susceptibility testing</li> </ul>	<ul style="list-style-type: none"> <li>• Slow (median detection time 2–3 days)</li> <li>• Sensitivity suboptimal, particularly if high volume (<math>\geq 60</math> ml) and a fungal blood culture bottle are not employed</li> </ul>
	Tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Enables species identification and subsequent susceptibility testing</li> </ul>	<ul style="list-style-type: none"> <li>• Selective media, proper spreading of the sample and 3 days of incubation required for optimal performance</li> </ul>
Microscopy	Cerebrospinal fluid, tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Highly sensitive, particularly if using fluorescent brightener staining</li> </ul>	<ul style="list-style-type: none"> <li>• No species identification</li> <li>• Lower sensitivity in absence of fluorescent brightener staining</li> </ul>
Histopathology	Tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Enables evaluation of tissue invasion and inflammation</li> </ul>	<ul style="list-style-type: none"> <li>• No species identification</li> <li>• Lower sensitivity in absence of fluorescent brightener staining</li> </ul>
Mannan antigen and antimannan antibody detection	Serum or plasma (EDTA) or cerebrospinal fluid	<ul style="list-style-type: none"> <li>• Increased diagnostic sensitivity when combined antigen and antibody testing is performed (although in neonates (in any sample) and in cerebrospinal fluid, antigen testing suffices)</li> </ul>	<ul style="list-style-type: none"> <li>• Heavy colonization (many non-sterile body sites culture positive for <i>Candida</i> spp. and/or with heavy growth in semi-quantitative culture) could cause positivity for blood testing</li> </ul>
$\beta$ -D-glucan detection	Serum or plasma (EDTA)	<ul style="list-style-type: none"> <li>• Pan-fungal marker</li> </ul>	<ul style="list-style-type: none"> <li>• No separation between <i>Candida</i> spp. and other fungi</li> <li>• Many sources for false positivity</li> </ul>
PCR	Blood (EDTA)	<ul style="list-style-type: none"> <li>• Rapid tests</li> <li>• Some commercial tests are FDA approved</li> </ul>	<ul style="list-style-type: none"> <li>• Commercial tests are expensive</li> <li>• May not detect all species</li> </ul>

Diagnostic test	Specimen(s)	Advantages	Disadvantages
Fungal culture	Blood	<ul style="list-style-type: none"> <li>• Enables species identification and subsequent susceptibility testing</li> </ul>	<div style="border: 1px solid blue; background-color: #ffe6e6; padding: 5px; text-align: center;"> <b>Sensitivity 21-71% Specificity NA</b> </div>
	Tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Enables species identification and subsequent susceptibility testing</li> </ul>	
Microscopy	Cerebrospinal fluid, tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Highly sensitive, particularly if using fluorescent brightener staining</li> </ul>	<ul style="list-style-type: none"> <li>• No species identification</li> <li>• Lower sensitivity in absence of fluorescent brightener staining</li> </ul>
Histopathology	Tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Enables evaluation of tissue invasion and inflammation</li> </ul>	<ul style="list-style-type: none"> <li>• No species identification</li> <li>• Lower sensitivity in absence of fluorescent brightener staining</li> </ul>
Mannan antigen and antimannan antibody detection	Serum or plasma (EDTA) or cerebrospinal fluid	<ul style="list-style-type: none"> <li>• Increased diagnostic sensitivity when combined antigen and antibody testing is performed (although in neonates (in any sample) and in cerebrospinal fluid, antigen testing suffices)</li> </ul>	<ul style="list-style-type: none"> <li>• Heavy colonization (many non-sterile body sites culture positive for <i>Candida</i> spp. and/or with heavy growth in semi-quantitative culture) could cause positivity for blood testing</li> </ul>
$\beta$ -D-glucan detection	Serum or plasma (EDTA)	<ul style="list-style-type: none"> <li>• Pan-fungal marker</li> </ul>	<ul style="list-style-type: none"> <li>• No separation between <i>Candida</i> spp. and other fungi</li> <li>• Many sources for false positivity</li> </ul>
PCR	Blood (EDTA)	<ul style="list-style-type: none"> <li>• Rapid tests</li> <li>• Some commercial tests are FDA approved</li> </ul>	<ul style="list-style-type: none"> <li>• Commercial tests are expensive</li> <li>• May not detect all species</li> </ul>




Diagnostic test	Specimen(s)	Advantages	Disadvantages
Fungal culture	Blood	<ul style="list-style-type: none"> <li>• Enables species identification and subsequent susceptibility testing</li> </ul>	<ul style="list-style-type: none"> <li>• Slow (median detection time 2–3 days)</li> <li>• Sensitivity suboptimal, particularly if high volume (<math>\geq 60</math> ml) and a fungal blood culture bottle are not employed</li> </ul>
	Tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Enables species identification and subsequent susceptibility testing</li> </ul>	<ul style="list-style-type: none"> <li>• Selective media, proper spreading of the sample and 3 days of incubation required for optimal performance</li> </ul>
Microscopy	Cerebrospinal fluid, tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Highly sensitive, particularly if using fluorescent brightener staining</li> </ul>	<ul style="list-style-type: none"> <li>• No species identification</li> <li>• Lower sensitivity in absence of fluorescent brightener staining</li> </ul>
Histopathology	Tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Enables evaluation of tissue invasion and inflammation</li> </ul>	<ul style="list-style-type: none"> <li>• No species identification</li> <li>• Lower sensitivity in absence of fluorescent brightener staining</li> </ul>
Mannan antigen and antimannan antibody detection	Serum or plasma (EDTA) or cerebrospinal fluid	<ul style="list-style-type: none"> <li>• Increased diagnostic sensitivity when combined antigen and antibody testing is performed (although in neonates (in any sample) and in cerebrospinal fluid, antigen testing suffices)</li> </ul>	<ul style="list-style-type: none"> <li>• Heavy colonization (many non-sterile body sites culture positive for <i>Candida</i> spp. and/or with heavy growth in semi-quantitative culture) could cause positivity for blood testing</li> </ul>
$\beta$ -D-glucan detection	Serum or plasma (EDTA)	<ul style="list-style-type: none"> <li>• Pan-fungal marker</li> </ul>	<ul style="list-style-type: none"> <li>• No separation between <i>Candida</i> spp. and other fungi</li> <li>• Many sources for false positivity</li> </ul>
PCR	Blood (EDTA)	<ul style="list-style-type: none"> <li>• Rapid tests</li> <li>• Some commercial tests are FDA approved</li> </ul>	<ul style="list-style-type: none"> <li>• Commercial tests are expensive</li> <li>• May not detect all species</li> </ul>

Diagnostic test	Specimen(s)	Advantages	Disadvantages
Fungal culture	Blood	<ul style="list-style-type: none"> <li>• Enables species identification and subsequent susceptibility testing</li> </ul>	<ul style="list-style-type: none"> <li>• Slow (median detection time 2–3 days)</li> <li>• Sensitivity suboptimal, particularly if high volume (<math>\geq 60</math> ml) and a fungal blood culture bottle are not employed</li> </ul>
	Tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Enables species identification and subsequent susceptibility testing</li> </ul>	<ul style="list-style-type: none"> <li>• Selective media, proper spreading of the sample and 3 days of incubation required for optimal performance</li> </ul>
Microscopy	Cerebrospinal fluid, tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Highly sensitive, particularly if using fluorescent brightener staining</li> </ul>	<ul style="list-style-type: none"> <li>• No species identification</li> <li>• Lower sensitivity in absence of fluorescent brightener staining</li> </ul>
Histopathology	Tissue and sterile body fluids	<ul style="list-style-type: none"> <li>• Enables evaluation of tissue invasion and inflammation</li> </ul>	<ul style="list-style-type: none"> <li>• No species identification</li> <li>• Lower sensitivity in absence of fluorescent brightener staining</li> </ul>
Mannan antigen and antimannan antibody detection	Serum or plasma (EDTA) or cerebrospinal fluid	<ul style="list-style-type: none"> <li>• Increased diagnostic sensitivity when combined antigen and antibody testing is performed (although in neonates (in any sample) and in cerebrospinal fluid, antigen testing suffices)</li> </ul>	<p><b>Sensitivity 79-87% Specificity 82-90%</b></p>
$\beta$ -D-glucan detection	Serum or plasma (EDTA)	<ul style="list-style-type: none"> <li>• Pan-fungal marker</li> </ul>	<p><b>Sensitivity 65-100% Specificity 31-79%</b></p>
PCR	Blood (EDTA)	<ul style="list-style-type: none"> <li>• Rapid tests</li> <li>• Some commercial tests are FDA approved</li> </ul>	<p><b>Sensitivity 82-98% Specificity 87-98%</b></p>



# Candida cerebral abscess

## Features on Neuroimaging



Cerebral magnetic resonance imaging (MRI) revealed innumerable small ( 1 cm) ring-enhancing lesions within the supratentorial white matter with abundant surrounding vasogenic edema

A 57-year-old homeless man with a history of uncontrolled diabetes mellitus type 2 and prior intravenous drug abuse was admitted to our hospital after being found unresponsive

PE : the patient was afebrile with a heart rate of 68 BPM BP 128/77 mmHg  
The patient was cachectic with **diffuse folliculitis and skin excoriations**  
No heart murmur or evidence of oropharyngeal candidiasis was found on physical exam

Neurological examination revealed lethargy and disorientation

Stereotactic biopsy of a lesion in the right frontal lobe to obtain an accurate diagnosis

GMS stain of the aspirated material revealed fungal elements, and *Candida albicans* was obtained in culture



# Treatment for CNS Candidiasis

## IDSA guidelines recommended treatment of CNS Candidiasis

**Liposomal AmB 5 mg/kg daily** with or without oral flucytosine 25 mg/kg 4 times daily

For step-down therapy after the patient has responded to initial treatment :

**Fluconazole 400 –800 mg (6–12 mg/kg) daily**

Therapy should continue until all signs and symptoms and CSF and radiological abnormalities have resolved

Infected CNS devices, including ventriculostomy drains, shunts, stimulators, prosthetic reconstructive devices, and biopolymer wafers that deliver chemotherapy **should be removed** if possible

For patients in whom a ventricular device **cannot** be removed, **AmB deoxycholate** could be administered through the device **into the ventricle** at a dosage ranging from 0.01mg to 0.5 mg in 2 mL 5% dextrose in water



# Micafungin

Micafungin sodium

sterile pwdr (เฉพะาะ 50mg)

๑(2) 5.2 Antifungal drugs

เงื่อนไข : ใช้รักษา Invasive candidiasis ที่ดื้อต่อ ยา fluconazole หรือไม่สามารใช้ conventional amphotericin B ได้ โดยมีแนวทางกำกับการใช้ยาเป็นไปตามรายละเอียดในภาคผนวก 3

Fluconazole ใช้รักษา Candida albicans และ Candida non-albicans Candida

Triazole 7 วัน

Fluconazole 5 วัน

Amphotericin B ใช้รักษา Candida albicans และ Candida non-albicans Candida



GFR < 60 ml/min CKD / on long term RRT

ข้อห้ามใช้

# Rhinocerebral Mucormycosis



# Rhinocerebral Mucormycosis



Changes in iron metabolism in diabetes related to mucormycosis pathogenesis

# Clinical Features of Mucormycosis

- Nasal obstruction or congestion with noisy breathing
- Headache, odontalgia, sinusitis with low-grade fever and unilateral facial swelling, maxillary pain and hyposmia or anosmia

**CNS invasion** presenting as : seizures, coma , CN palsy, Hemiplegia, Brain Abscess

Atypical clinical presentations with facial nerve palsy caused by extension of the disease into the infratemporal fossa

2nd Most common invasion in patient with DM : Pulmonary involvement , 13%

3rd Most common invasion in patient with DM : Skin involvement , 10%



# Mucormycosis


## Diagnosis

- Proven mucormycosis in the context of a compatible infectious process, tissue biopsies and/or positive cultures obtained from sterile sites
- Probable mucormycosis diagnosis requires the association of host factors : DM with clinical and/or radiological signs compatible with mucormycosis, and direct examination or a positive culture isolated from a sample obtained from a pathological site




# Rhinocerebral mucormycosis

Spreading via direct extension with angioinvasion





J Fungi 2018; 4(90): 1-17.

Left eye ptosis and left cheek edema  
CT: soft tissue opacification of left maxillary and ethmoid sinuses





**Fig. 22.25** Orbital mucormycosis. Image is a post-contrast axial CT section through the ethmoidal bridge. This case illustrates changes of a left subperiosteal, mesial, orbital abscess. There is little evidence of ethmoid sinusitis. However, it is not uncommon, as in this case, that invasive fungal infections arising either from sinusitis or rhinitis may have only subtle mucosal thickening on imaging, yet still can permeate bone creating soft tissue abscesses in the skull base





(Left) Axial FLAIR MR in a patient with ALL status post stem cell transplant demonstrates large hyperintense areas involving the cortex, subcortical white matter, and basal ganglia. There is mass effect on the lateral ventricles greater on the right.  
(Right) Axial DWI in the same patient shows corresponding large areas of restricted diffusion due to infarction.





(Left) Axial SWI MR in the same patient shows multiple punctate "blooming" foci within the areas of FLAIR signal abnormality consistent with petechial hemorrhages.  
(Right) Axial T1+C MR in the same patient does not show any significant enhancement

**Angioinvasive mucormycosis was found at surgery.**

**Angioinvasive fungi (Mucor, Aspergillus) produce enzyme elastase which compromises blood vessel wall leading to inflammatory reaction, vasculitis, thrombosis, and infarction**





**Fig. 22.24** (a) A 63-year-old male with disseminated mucor infection. Shows CNS vasculitis with neutrophils invading CNS parenchymal vessels with early vessel wall destruction (H&E, 20 $\times$ ). (b) Same patient. Features a Gomori methenamine silver (GMS)-stained speci-

men demonstrating angioinvasion by fungi with broad aseptate hyphae and right-angle branching (GMS, 20 $\times$ ) (Both courtesy of Anthony Yachnis, MD, and Kelly Devers, MD, University of Florida College of Medicine)



# Rhinocerebral Mucormycosis

## Treatment

- Treatment of the condition is based on three main principles
  - **Rapid reversal of underlying predisposing factors**
  - Antifungal therapy with **L-amphotericin B 1 mg/kg/day**
  - Surgical intervention : Extensive surgical debridement of necrotic tissue

# Parasitic disease of the Nervous system in Thailand



# Parasitic disease of the Nervous system in Thailand

*Angiostrongylus costaricensis*

*Gnathostoma spinigerum*

*Cysticercus cellulosae*

TABLE 11-1

## Selected Helminthic Infections of the Central Nervous System

Organism	Disease	Neurologic Localization/Syndrome	Geographic Distribution
<b><i>Taenia solium</i></b>	Cysticercosis	Parenchymal and extraparenchymal cysts, headache, epilepsy, hydrocephalus, stroke	Central America, South America, sub-Saharan Africa, Asia
<b><i>Echinococcus granulosus</i></b>	Hydatid disease	Cystic brain disease, headache, epilepsy	Mediterranean, Middle East, East Africa, Russia, South America
<b><i>Angiostrongylus cantonensis</i></b>	Angiostrongyliasis	Eosinophilic meningitis	Southeast Asia, Pacific Islands, Caribbean
<b><i>Gnathostoma</i> species</b>	Gnathostomiasis	Eosinophilic meningitis, cranial neuropathies, sudden severe headache or radicular pain	Southeast Asia, Japan, Central America, South America
<b><i>Schistosoma mansoni</i>, <i>Schistosoma haematobium</i></b>	Schistosomiasis	Myeloradiculopathy, encephalitis	South America, Caribbean, sub-Saharan Africa, Southwest Asia, Middle East
<b><i>Schistosoma japonicum</i></b>	Schistosomiasis	Encephalitis	Southeast Asia, Japan, China, Philippines
<b><i>Paragonimus</i> species</b>	Paragonimiasis	Parenchymal granuloma, arachnoiditis, epilepsy, meningitis	Southeast Asia, East Asia




# Angiostrongylus cantonensis


## Infection of CNS



# Angiostrongylus cantonensis



- A) Differential interference contrast microscopy image of third-stage (L3) infective larvae recovered from a slug. L3 larvae are about 0.45 by 0.02 mm and present cuticle with faint transverse striations
- B) Higher magnification of demarcated region in A showing terminal projection on the tip of the tail (arrow) which is characteristic of *A. cantonensis*
- C) Adult female and tail of adult male
- D) worms recovered from rat lungs





# Angiostrongylus cantonensis Infection of CNS


## Clinical Manifestation

Eosinophilic meningitis

Encephalitis/encephalomyelitis

Radiculitis

Cranial nerve abnormalities and ataxia



A patient with ocular angiostrongyliasis. Blurred vision with chemosis is presenting symptom



# Angiostrongylus cantonensis Infection of CNS

## Clinical Manifestation

Observation/Finding*	Present, No.	Absent, No.	Proportion with symptom/sign present (%) <sup>†</sup>
<b>Symptom/Sign</b>			
Subjective fever	8	2	8/10 (80)
Generalized weakness	7	2	7/9 (78)
Headache	6	2	6/8 (75)
Numbness/Tingling	3	3	3/6 (50)
Photophobia	4	5	4/9 (44)
Visual changes	3	4	3/7 (43)
Vomiting	3	6	3/9 (33)
Stiff neck	2	7	2/9 (22)
Rash	2	7	2/9 (22)
Nausea	1	5	1/6 (17)
Phonophobia	1	6	1/7 (14)
Abdominal pain	1	7	1/8 (13)
Itching	1	8	1/9 (11)
Diarrhea	3	NA	NA
Hyperesthesias/diffuse allodynia	2	NA	NA

Observation/Finding*	Present, No.	Absent, No.	Proportion with symptom/sign present (%) <sup>†</sup>
<b>Physical exam</b>			
<b>Vital signs</b>			
Fever (temperature $\geq 100.4^\circ\text{F}$ [ $\geq 38.0^\circ\text{C}$ ])	3	8	3/11 (27)
Tachycardia ( $>100$ bpm in adults aged $\geq 16$ yrs, age-dependent in persons aged $<16$ yrs)	1	10	1/11 (9)
Hypoxia ( $\text{O}_2$ saturation $<90\%$ )	0	10	0/10 (0)
<b>Neurologic exam findings</b>			
Cranial nerve deficits	5	6	5/11 (45)
Nuchal rigidity	4	8	4/12 (33)
Focal weakness	3	7	3/10 (30)
Paresthesias	1	7	1/8 (12)
Loss of consciousness	0	10	0/10 (0)
Irritability	3	NA	NA
Ataxia	2	1 <sup>§</sup>	NA

Symptoms, physical exam findings, and laboratory results for 12 patients with angiostrongyliasis with detectable *A. cantonensis* DNA on polymerase chain reaction testing



# Angiostrongylus cantonensis Infection of CNS

## Clinical Manifestation

- **Prodromal syndromes** due to the passage of L3 larvae through different organs
  - Enteritis can be associated with invasion of the gastrointestinal tract
  - Cough, rhinorrhea, and sore throat can develop when worms pass through the lungs and trachea
  - Fever and malaise are nonspecific symptoms of infection and can also occur before the development of CNS disease

The **incubation period** for the development of eosinophilic meningitis is typically about **2 weeks**, which coincides with the time it takes for the L3 larvae to migrate into CNS tissue and incite a reaction, it can range from one day to several months

# Angiostrongylus cantonensis Infection of CNS

## Diagnosis

An important factor suggesting *A. cantonensis* infection is a **history of eating uncooked fresh water snails, crustaceans, or monitor lizard's liver during the 2–3 months** before the neurological symptoms appear.

Laboratory tests supporting diagnosis include complete blood count, CSF fluid analysis, immunological examination, and radiological examination.



# Angiostrongylus cantonensis Infection of CNS

## Diagnosis

Definitive diagnosis is made by detection of **A. cantonensis larvae** in the CSF

Detection rate is frequently low which makes the diagnosis primarily based on clinical history, CSF eosinophilia, and immunological tests

### CSF analysis

CSF leukocyte count is often between 150 and 2,000 cells/ $\mu$ L

Eosinophilic pleocytosis exceeds 10% in more than 95% of patients

The CSF protein concentration is elevated


Glucose level is normal or slightly reduced

Opening CSF pressures are elevated in nearly 40% of cases

Immunological examinations ELISA or the immunoblotting test ,Antigen with a molecular weight of 29 or 31 kDa is highly specific for A. cantonensis

The specificity of was 100% in patients with eosinophilic meningitis






a) Meningeal infiltration by eosinophils, macrophages, and lymphocytes

b) Distinct tracks within the brain parenchyma associated with cell debris, micro thrombi and inflammatory cells

c) Presence of eosinophilic granulomas and sometimes Charcot-Leyden crystals surrounding dead worms



Cross-section of two *Angiostrongylus cantonensis* larvae in the spinal cord



# Angiostrongylus cantonensis Infection of CNS

## Laboratory : CSF

Patient with alteration of consciousness should always receive CT brain before LP

Observation/Finding*	Present, No.	Absent, No.	Proportion with symptom/sign present (%) <sup>†</sup>
<b>Laboratory results on initial evaluation</b>			
<b>Cerebrospinal fluid</b>			
Pleocytosis of CSF ( $\geq 6$ WBC/mm <sup>3</sup> )	12	0	12/12 (100)
CSF eosinophilia (eosinophils $\geq 10\%$ of all leukocytes in CSF or $\geq 10$ eosinophils/mm <sup>3</sup> )	10	2 <sup>¶</sup>	10/12 (83)
Hypoglycorrhachia (CSF glucose $< 40$ mg/dL)	6	5	6/11 (54)
<b>Complete blood count</b>			
Peripheral eosinophilia ( $> 600$ eosinophils/mm <sup>3</sup> )	8	2	8/10 (80)
Leukocytosis ( $> 11 \times 10^3$ WBC/mm <sup>3</sup> in persons aged $> 21$ yrs, age-dependent in persons aged $\leq 21$ yrs)	3	9	3/12 (25)

Symptoms, physical exam findings, and laboratory results for 12 patients with angiostrongyliasis with detectable *A. cantonensis* DNA on polymerase chain reaction testing



# Angiostrongylus cantonensis Infection of CNS

Laboratory : CSF


An eosinophil count of more than 798 cells , for the diagnosis of meningitic angiostrongyliasis : sensitivity 76.6% , specificity 80.2%, PPV 58.1%, and NPV 90.5%

The average leukocyte count in CSF fluid is 700 cells/mm<sup>3</sup> and can be as high as 5000 cells/mm<sup>3</sup>

Protein levels usually do **not** exceed 500 mg/dL

Sugar levels in CSF fluid can be as **low** as 17% when compared to plasma glucose

Abnormalities in CSF fluid from meningitis and encephalitis patients are similar in terms of **turbidity like coconut juice** and opening pressure was high in 38%



Prakaykaew Charunwatthana and Yupaporn Wattanagoon Hunter's Tropical Medicine and Emerging Infectious Diseases, 122, 891-894



# Angiostrongylus cantonensis Infection of CNS

## Imaging

The absence of focal lesions on CT or MRI scans of the brain distinguishes *A. cantonensis* meningitis from other helminthic infections of the CNS (gnathostomiasis or neurocysticercosis)

Nonspecific abnormalities MRI in patients with the encephalitic form


tract-like lesion

white matter involvement

nodular enhancement

myelitis

Radiological examination is not specific





# Angiostrongylus cantonensis Infection of CNS

## Treatment

There is **no specific treatment** for *A. cantonensis* infection

The best treatment for meningitic angiostrongyliasis is **prednisolone 60 mg/day for 2 weeks**

2-week course of albendazole tends to decrease the duration of headaches when compared to placebo

Studies of the **combination** of prednisolone with antihelminthics found it to be as **effective** as prednisolone alone




# Neurognathostomiasis



# Gnathostoma spinigerum


The tissue nematode involved, *Gnathostoma spinigerum*, because of its high motility, may cause widespread damage in the spinal cord and brain stem



7 AL3 and/or immature adults undergo aberrant migration in the human host.

Human becomes an accidental host by eating infected under-cooked fresh water fish

AL3 develop into adult worms in definitive host; form tumor in gastric wall.



A) Third-stage larva of the nematode *Gnathostoma* sp.  
 B) Scanning electronic microscopy image depicting head bulb with 4 cephalic hooklet rows  
 C) *Gnathostoma* sp. larvae in the flesh *Eleotris picta* fish  
 D) Cross- section of a *Gnathostoma* sp. larva in human skin biopsy sample (hematoxylin and eosin stain)



# Neurognathostomiasis

## Clinical Signs of Neurologic Involvement

- **Pain** Radicular pain is characteristically intermittent, severe, and localized to an arm, leg, or one side of the body
- **Myelitis** Paraplegia and quadriplegia, paraparesthesia, and urinary retention  
Some patients may develop Brown–Sequard or cauda equina syndrome
- Intracranial hemorrhage
- Subarachnoid hemorrhage
- Combination of these

# Clinical Signs

History of larva exposure : Regularly eating raw or undercooked meat

A history of The true incuba-tion period is always uncertain

Skin manifestations are the common suggestive signs for gnathostomiasis

two forms including intermittent migratory swelling and creeping eruption



Migratory swelling on left forearm caused by *G. spinigerum*



A patient with ocular gnathostomiasis. Ocular swelling is presenting symptom



# Clinical Signs of Neurologic Involvement

Table 1. Clinical presentation of 248 patients with neurognathostomiasis\*

Syndrome	Probable entry portal entry	Clinical signs and symptoms	No. (%) cases
Radiculomyelitis/myelitis/ myeloencephalitis	Intervertebral foramina along the spinal nerves and vessels	Sharp radicular pain and a spinal syndrome (paraplegia, monoplegia, quadriplegia, bladder dysfunction, sensory disturbances), can progress to cerebral involvement (myeloencephalitis)	140 (55)
Meningitis/ meningoencephalitis	Neural foramina of the skull base along the cranial nerves and vessels	Severe headache, stiffness of the neck, cranial nerve palsies, disturbance of consciousness, focal neurologic signs	77 (30)
Intracerebral hemorrhage	Intervertebral or neural foramina	Headache, sudden-onset focal neurologic signs	21 (8)
Subarachnoid hemorrhage	Intervertebral or neural foramina	Thunderclap headache, meningeal signs	16 (7)

\*Because the larvae migrate, patients can have sequential signs and symptoms; thus, the total number of clinical syndromes shown exceeds the number of reported patients.

# Neurognathostomiasis

## Diagnosis : CSF Studies

Normal or high normal opening pressure

Number of white blood cells in the CSF ranges from 20 to 1430 cells/mm<sup>3</sup>

**CSF Eosinophilia** in patients is usually prominent , ranges from 20 - 1430 cells/mm<sup>3</sup>

Median values were 40%-54%


CSF has been reported as xanthochromic or bloody (64%)

CSF glucose is usually normal or only mildly reduced

Mild elevation of protein




# Diagnosis : Neuroradiologic Features



- A) Axial T1-weighted image showing small hemorrhage in the right basal ganglia  
B) Sagittal T2-weighted images showing diffuse cord enlargement with longitudinal T2 hyperintensity  
C) Axial T1-weighted image showing a hemorrhagic track in the tegmentum of the pons  
D) Coronal T1-weighted postgadolinium image, showing the longitudinal extension of the same hemorrhagic track as in panel C  
Images from K. Sawanyawisuth et al.



# Diagnosis : Neuroradiologic Features



MRI of the brain showed hemorrhagic tract at corpus callosum and subarachnoid hemorrhage at left sylvian fissure



# Neurognathostomiasis

## Diagnosis : Immunodiagnosis

Two methods have been established for clinical routine : ELISA and Western blot by using crude *Gnathostoma* spp. antigens from larval extract

The 24-kD band on Western blot was shown to have **nearly 100% specificity** for gnathostomiasis

The current practice for serologic diagnosis is to use the ELISA (e.g., multiple-dot ELISA) as the first step and to confirm the results by Western blot

# Neurognathostomiasis

## Treatment

Albendazole (800 mg/d for for 3-4 weeks and 400 mg 2×/d for 4 weeks)

Corticosteroids have been used in neurognathostomiasis to treat cerebral and spinal edema, might prevent or alleviate paradoxical worsening after initiation of antihelminthic treatment




# Neurocysticercosis

# Cysticercus cellulosae

Carried by blood stream, lodge in small blood vessels develop into viable cysts after 2-3 months

Oncosphere-larva of tapeworm through stomach wall





# Neurocysticercosis

## Clinical signs and symptoms

*Taenia solium*, commonly results in epilepsy, and sometimes increased intracranial pressure from intraventricular obstruction or from basal arachnoiditis

Spinal cord and cauda equina involvement occurs much less frequently

Cysticercus complement fixation tests on the CSF and computerised axial tomography have been found to be of great diagnostic value

Depend on number, location, growth, stage of degeneration of cysts, host factors, parasitic genotype

Most of the pathophysiology of cysticercosis results from acute or chronic **inflammatory responses** against the membranes and residual antigens of degenerating cysts

Mass effects & mechanical obstruction of cerebrospinal fluid (CSF) flow

# Neurocysticercosis

## Clinical signs and symptoms

- 78.8% of patients presented with seizures-GTC
- 37.9% presented with headaches
- 16% had focal neurological deficits
- 11.7% showed signs of intracranial hypertension
- 7.9% had meningitis, 6% had gait abnormalities
- 5.6% reported visual changes
- 4.5% had an altered mental state
- 2.8% had cranial nerve palsies



# Neurocysticercosis

## Parenchymal disease

: Frequently locate at watershed area between white-grey matter

- Viable cyst
- Degenerating cyst
- Calcified cyst

## Extra parenchymal disease

: Large basal subarachnoid lesion

Small cyst at choroid plexus  
“Ventricular cyst”

> obstruction of 4th ventricle

- Ventricular neurocysticercosis
- Subarachnoid disease of brain tissue
- Basal subarachnoid neurocysticercosis

**Table 1.** Differences between parenchymal and extraparenchymal neurocysticercosis.

	Parenchymal	Extraparenchymal		
		Subarachnoideal		Intraventricular
		Cysts in basal cisterns	Arachnoiditis	
Main clinical manifestations	Seizures, focal deficits	Cranial hypertension	Cranial hypertension, symptoms of cranial neuropathy	Cranial hypertension, Bruns' syndrome
Pathology	Focal tissue inflammation and/or gliosis	Mass effect	Thickening of leptomeninges	Obstruction of CFS circulation
CSF analysis	Often inconclusive	Inflammatory pattern	Inflammatory pattern	Inflammatory pattern (less intense than in subaracnoidal parasites)
Immunological tests	Antibodies >50%, antigens <50%	–	Antibodies >90%, antigens >70%	Antibodies >90%, antigens >70%
Complications	Epilepsy, cognitive decline	Hydrocephalus, vasculitis, cerebral infarcts, chiasmatic syndrome	Hydrocephalus, vasculitis, cerebral infarcts, chiasmatic syndrome	Hydrocephalus, ependymitis, sudden death
Prognosis	Good, clinical manifestations usually self-limited	'Malignant,' clinical manifestations usually progressive	'Malignant,' usually permanent sequelae	Heterogeneous. Can be good after excision by endoscopic surgery



## 1. Parenchymal neurocysticercosis

---

**Definitive parenchymal neurocysticercosis<sup>a</sup>**, one of the following:

- (1) Parenchymal cyst with pathological diagnosis
- (2) Single or multiple active parenchymal cysts, with at least one cyst with scolex on CT or MRI
- (3) Multiple parenchymal vesicles without scolex associated with at least one of the following:
  - (a) Seizures: focal or generalized tonic-clonic
  - (b) Positive serum or CSF immunological test (ELISA, EITB)
- (4) Any combination of the parenchymal cysticercus in different evolutive stages: vesicular with or without scolex, degenerative (colloidal or nodular) and calcified

**Probable parenchymal neurocysticercosis**, one of the following:

- (1) Single parenchymal calcification or vesicle (without scolex) or degenerating cyst(s), establishing differential diagnoses with other etiologies, associated with at least two of the following:
  - (a) Seizures: focal or generalized tonic-clonic
  - (b) Subcutaneous or muscle cysts location confirmed by biopsy
  - (c) Positive serum or CSF immunological test (ELISA, EITB)
  - (d) Plain X-ray films showing 'cigar-shaped' calcifications
  - (e) Individual who lives or has lived in or has traveled frequently to endemic countries
- (2) Multiple parenchymal calcifications in an individual who lives or has lived in or has traveled frequently to endemic countries and in whom clinical state excludes other etiologies of calcifications

Neurocysticercosis most commonly manifests in the parenchyma of the brain and typically involves the cerebral hemispheres, Basal ganglia, brainstem, and cerebellum

The lesions are commonly found at the graye-white matter junction, presumably resulting from deposition of the larvae in terminal small vessels of these regions

## **2. Extraparenchymal neurocysticercosis** (intraventricular/basal subarachnoid)

**Definitive extraparenchymal neurocysticercosis**, one of the following:

- (1) Extraparenchymal cyst with pathological diagnosis
- (2) One or more extraparenchymal cysts on MRI special sequences with scolex in at least one of them
- (3) One or more extraparenchymal cysts on MRI special sequences without scolex associated with at least two of the following:
  - (a) Hydrocephalus
  - (b) Inflammatory CSF
  - (c) Positive CSF immunological test (ELISA, EITB)
  - (d) Presence of single or multiple calcifications or parenchymal vesicular or degenerative cyst

## **3. Definitive parenchymal and extraparenchymal neurocysticercosis**

Combination of the above definitive parenchymal and definitive extraparenchymal criteria



# Investigation : Serology

**EITB (enzyme-linked immunoelectrotransfer blot)** : detect antibodies in the serum that recognize a range of specific antigens, identified and cloned from *T. solium* cysts -very specific for identifying exposure to *T. solium*

> Lacks sensitivity in patients with low disease burden

**Enzyme-linked immunosorbent assay (ELISA)**-based antigen-detection

tests that use monoclonal antibodies

	ELISA		EITB	
Specimen	Serum	CSF	Serum	CSF
Sensitivity (%)	41.0	71	86	86
Specificity (%)	95.7	95.7	92.8	92.8

# Investigation : Serology

## Serial measurements of Ag levels


- to establish the efficacy of treatment,
- indicate clearance of parasites from the patient,
- suggest when antihelminthic treatment can be stopped

## Monitoring drug efficacy for follow-up of treated individuals




# Imaging spectrum of Neurocysticercosis

## Vesicular stage (active)




A




B

Small CSF-like cyst with thin wall and an eccentrically located scolex, no contrast enhancement of the cyst's wall, no surrounding tissue edema.

## Colloidal Vesicular stage (active)




A



B

The density and signal intensity of the cystic fluid change from that of CSF. The cystic wall is thicker. The scolex becomes ill defined and finally shrinks in its size. Ring-like enhancement is seen. The surrounding tissue edema is obvious.

## Granular Nodular stage (active)



Small enhancing cyst or nodule, with mild surrounding edema and little mass effect.

## Nodular Calcified stage (non active)



Small calcified nodule, no surrounding edema, better seen on CT.



# Neurocysticercosis

## Treatment

	Parenchymal <sup>f</sup>	Cysts in basal cisterns	Subarachnoideal Arachnoiditis	Intraventricular
Symptomatic therapy	Antiseizures, analgesics, and steroids drugs according to clinical manifestations <sup>a</sup>	Ventriculo peritoneal shunt for clinical intracranial hypertension management and steroids <sup>a</sup>	Analgesics and steroids drugs according to clinical manifestations <sup>a</sup> ; ventriculo peritoneal shunt for hydrocephalus <sup>a</sup>	Ventriculo peritoneal shunt for hydrocephalus <sup>a</sup> and steroids <sup>a</sup>
Antihelminthic drugs	Albendazole or praziquantel <sup>d</sup> for vesicular cysts <sup>b</sup> or single enhancing cyst <sup>c</sup>	Albendazole or praziquantel <sup>a,e</sup>	No indication <sup>a</sup>	Albendazole or praziquantel <sup>a,e</sup>
Surgical treatment	Excision of 'giant' cyst with mass effect <sup>a</sup>	No indication <sup>a</sup>	No indication <sup>a</sup>	Neuroendoscopic excision <sup>a</sup>

<sup>a</sup>There is no controlled clinical trial; <sup>b</sup>based on controlled clinical trials (30–40% of disappearance of cysts); <sup>c</sup>controversial results of clinical trials; <sup>d</sup>albendazole 15 mg/kg/day for 1 week, praziquantel 50 mg/kg/day for 2 weeks (usual doses recommended by consensus); <sup>e</sup>doses of albendazole or praziquantel have not been systematically standardized although 30 mg/kg of albendazole was reported more efficient than the classical doses of 15 mg/kg/day in one randomized study (Gongora-Rivera et al.); <sup>f</sup>includes cysts in sulcus of the convexity.



# Eosinophilic Meningitis

presence of at least 10% eosinophils in the total CSF leukocyte count

**TABLE 122.1** Differential Diagnosis of Eosinophilic Meningitis

Parasitic Infections	Non-Parasitic Infections	Non-Infectious Causes
<ul style="list-style-type: none"> <li>• Angiostrongyliasis</li> <li>• Gnathostomiasis</li> <li>• Baylisascariasis</li> <li>• Toxocariasis</li> <li>• Cysticercosis</li> <li>• Paragonimiasis</li> <li>• Schistosomiasis</li> <li>• Fascioliasis</li> <li>• Trichinellosis</li> </ul>	<ul style="list-style-type: none"> <li>• Coccidioidomycosis</li> <li>• Cryptococcosis</li> <li>• Myiasis</li> </ul>	<ul style="list-style-type: none"> <li>• Idiopathic hypereosinophilic syndromes</li> <li>• Sarcoidosis</li> <li>• Leukemia or lymphoma with CNS involvement</li> <li>• Ventricular shunts</li> <li>• Post-vaccination</li> <li>• Drug induced:               <ul style="list-style-type: none"> <li>• NSAIDs: ibuprofen</li> <li>• Antibiotics: ciprofloxacin, trimethoprim–sulfamethoxazole, vancomycin, gentamicin</li> <li>• Myelography contrast agents</li> </ul> </li> </ul>

*CNS*, Central nervous system; *NSAIDs*, nonsteroidal anti-inflammatory drugs.

Thank you